Delivery Order SPE2DR25D9367-SPE2DR26FKKF1

The Defense Logistics Agency awarded a $37,722.26 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This delivery order, issued on December 8, 2025, with an ultimate completion date of December 9, 2025, represents a routine pharmaceutical procurement under DLA's Medical Supply Chain operations. No set-aside designation was applied to this award, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. was selected as the awardee based on its established performance as a critical supplier within the federal pharmaceutical supply chain.

This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $500 million ceiling and a performance period extending through December 31, 2036. The PPV-G GEN V program, part of a $30.3 billion acquisition strategy, establishes multiple regional prime vendor contractors to supply comprehensive pharmaceutical products—including branded and generic prescription medications, biologics, vaccines, and medical consumables—to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's selection as a prime vendor contractor positions the company to support recurring medical supply needs across the global military healthcare system, with this delivery order exemplifying the routine pharmaceutical fulfillment conducted under the broader contract vehicle.